The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis.
Chenchula SantennaKota VidyasagarKrishna Chaitanya AmarneniSai Nikhila GhantaBalakrishnan SadasivamSaman PathanR PadmavathiPublished in: Therapeutic advances in drug safety (2021)
Ten-day remdesivir is a safe antiviral drug with common adverse events in comparison to placebo.The rate of serious adverse events and grade 3 adverse events were significantly lower in 10-day remdesivir in comparison to placebo/5-day remdesivir.There was no significant difference in the rate of tolerability and mortality reduction in 10-day remdesivir over placebo/5-day remdesivir.There were no new safety signals reported in vulnerable populations, paediatric, pregnant and lactating women.
Keyphrases
- double blind
- placebo controlled
- open label
- cardiovascular events
- phase iii
- pregnant women
- emergency department
- intensive care unit
- risk factors
- clinical trial
- randomized controlled trial
- type diabetes
- cross sectional
- polycystic ovary syndrome
- insulin resistance
- pregnancy outcomes
- weight loss
- adverse drug
- drug induced